GET THE APP

Gene cancer immunogene therapy
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Gene cancer immunogene therapy


International Conference on Cancer Biology & Drug Delivery

September 18-19, 2017 | Philadelphia, USA

Jerzy Trojan

University of Santander, Colombia

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Antibodies to an oncoptrotein Alpha-fetoprotein, AFP, have constituted the first generation tool for cancer diagnostic and cancer therapy, especially of hepatocarcinoma. In the case of brain malignant tumor, glioblastoma, AFP being present as well in glial as in neuronal cells, another oncoprotein-IGF-I, specific for glial cells was selected. For therapy purpose, the second generation tool was created: the arrest of oncoprotein synthesis in cancer cells was performed on translation and transcription level in vitro using anti-gene anti IGF-I strategy (IGF-I antisense/triple helix, AS/TH). The created AS/TH cells, presented the following characteristics: absence of IGF-I; presence of IGF-I receptor; presence of MHC-I, B71 and B72 antigens; and presence of IL-6. The observed phenotypical characteristics became the standardized criteria for IGF-I AS/TH cell vaccines: while injected in cancer patients, the vaccines induced the antitumor immune response and stopped the progression of tumor development. In glioblastoma patients, the survival reached 2 years, and in some cases, up to 3-4 years.

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward